$ICCC News

ImmuCell Corporation 2026 Q2 - Results - Earnings Call Presentation

ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript

ImmuCell Reports Q2 2026 Results: Full Earnings Call Transcript

ImmuCell Q2 EPS $0.20 Up From $0.06 YoY, Sales $7.186M Up From $6.445M YoY

ImmuCell: First Defense With Better Execution

ImmuCell Q2 Total Product Sales Rises 12%

ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand

ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth

ImmuCell Q1 Earnings Call Highlights

ImmuCell Corporation (ICCC) Q1 2026 Earnings Call Transcript

ImmuCell Corporation 2026 Q1 - Results - Earnings Call Presentation

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026

ImmuCell Q1 EPS $0.21 Up From $0.16 YoY, Sales $10.357M Up From $8.067M YoY

Here’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity

ImmuCell And Norbrook Laboratories Reach Settlement Agreement, Norbrook To Pay $2M Following Expiration Of 2019 Supply Deal

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026

ImmuCell shares are trading higher after the company reported year-over-year increase in its Q1 preliminary sales results.

ImmuCell shares are trading higher after the company reported year-over-year increase in its Q1 preliminary sales results.

ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results

ImmuCell Reports Q1 Preliminary Sales $10.4M Up From 28.4% YoY